Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
Claus Garbe(University of Tübingen), Alexander M.M. Eggermont(University Medical Center Utrecht), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Axel Hauschild(University Hospital Schleswig-Holstein), Josep Malvehy(Universitat de Barcelona), Mark R. Middleton(University of Oxford), Alexander Stratigos(National and Kapodistrian University of Athens), Jean‐Jacques Grob(Aix-Marseille Université), Julia Newton‐Bishop(University of Leeds), Ketty Peris(Agostino Gemelli University Polyclinic), Hubert Pehamberger(Medical University of Vienna), Lars Bastholt(Odense University Hospital)
Cited by 579
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k